Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products.
It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.
The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis.
The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.
The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008.
Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -0.01 Decreased by -101.74% | 0.15 Decreased by -103.60% |
| May 9, 24 | -0.02 Decreased by -108.00% | 0.19 Decreased by -110.53% |
| Feb 15, 24 | -0.01 Decreased by -103.70% | 0.21 Decreased by -104.76% |
| Nov 9, 23 | 0.09 Decreased by -67.86% | 0.16 Decreased by -43.75% |
| Aug 8, 23 | 0.31 Increased by +47.62% | 0.25 Increased by +24.00% |
| May 4, 23 | 0.25 Increased by +19.05% | 0.24 Increased by +4.17% |
| Feb 16, 23 | 0.27 Increased by 0.00% | 0.27 |
| Nov 3, 22 | 0.28 Decreased by -15.15% | 0.27 Increased by +3.70% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 91.59 M Decreased by -19.47% | 31.09 M Increased by +102.94% | Increased by +33.95% Increased by +152.01% |
| Jun 30, 24 | 94.40 M Decreased by -12.09% | -860.00 K Increased by +99.92% | Decreased by -0.91% Increased by +99.91% |
| Mar 31, 24 | 74.88 M Decreased by -28.05% | -4.16 M Decreased by -109.10% | Decreased by -5.56% Decreased by -112.65% |
| Dec 31, 23 | 117.55 M Increased by +9.66% | -1.09 M Decreased by -102.22% | Decreased by -0.92% Decreased by -102.03% |
| Sep 30, 23 | 113.74 M Increased by +4.70% | 15.32 M Decreased by -69.55% | Increased by +13.47% Decreased by -70.92% |
| Jun 30, 23 | 107.38 M Increased by +10.44% | -1.06 B Decreased by -2.96 K% | Decreased by -989.17% Decreased by -2.69 K% |
| Mar 31, 23 | 104.06 M Increased by +6.70% | 45.71 M Increased by +17.82% | Increased by +43.93% Increased by +10.42% |
| Dec 31, 22 | 107.20 M Decreased by -8.48% | 48.87 M Increased by +18.11% | Increased by +45.59% Increased by +29.05% |